Xunlei Zhang

Dr. Xunlei Zhang


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
XQXue Qi
Xue Qi
JCJia Chen
Jia Chen
SWSheng Wei
Sheng Wei
JNJingyi Ni
Jingyi Ni
LSLi Song
Li Song
XZXunlei Zhang
Xunlei Zhang
Objective: Platelet-to-lymphocyte ratio (PLR), known as a key systemic inflammatory parameter, has been proved to be associated with response to neoadjuvant therapy in breast cancer (BC); however, the results remain controversial. This meta-analysis was carried out to evaluate the prognostic values of PLR in patients with BC treated with neoadjuvant chemotherapy (NACT). Design: Meta-analysis. Data sources: Relevant literature published on the following databases: PubMed, Embase, Web of Science databases and the Cochrane Library. Eligibility criteria: All studies involving patients with BC treated with NACT and peripheral blood pretreatment PLR recorded were included. Data extraction and synthesis: Two researchers independently extracted and evaluated HR/OR and its 95% CI of survival outcomes, pathological complete response (pCR) rate and clinicopathological parameters. Results: The last search was updated to 31 December 2022. A total of 22 studies with 5533 patients with BC treated with NACT were enrolled in the final meta-analysis. Our results demonstrate that elevated PLR value appears to correlate with low pCR rate (HR 0.77, 95% CI 0.67 to 0.88, p<0.001, I 2 =75.80%, P h <0.001) and poor prognosis, including overall survival (OS) (HR 1.90, 95% CI 1.39 to 2.59, p<0.001; I 2 =7.40%, P h =0.365) and disease-free survival (HR 1.97, 95% CI 1.56 to 2.50, p<0.001; I 2 =0.0%, P h =0.460). Furthermore, PLR level was associated with age (OR 0.86, 95% CI 0.79 to 0.93, p<0.001, I 2 =40.60%, P h =0.096), menopausal status (OR 0.83, 95% CI 0.76 to 0.90, p<0.001, I 2 =50.80%, P h =0.087) and T stage (OR 1.05, 95% CI 1.00 to 1.11, p=0.035; I 2 =70.30%, P h =0.005) of patients with BC. Conclusions: This meta-analysis demonstrated that high PLR was significantly related to the low pCR rate, poor OS and disease-free survival (DFS) of patients with BC treated with NACT. Therefore, PLR can be used as a potential predictor biomarker for the efficacy of NACT in BC.

9 May 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JNJingyi Ni
Jingyi Ni
XQXue Qi
Xue Qi
CJConghui Jin
Conghui Jin
WXWeiwei Xu
Weiwei Xu
XLXinghui Li
Xinghui Li
XZXunlei Zhang
Xunlei Zhang
Objective: The purpose of this study was to evaluate the predictive values of systemic immune-inflammatory index (SII), prognostic nutrition index (PNI), change of SII (ΔSII), change of PNI (ΔPNI) and ΔPNI-ΔSII score in patients with neoadjuvant chemotherapy for breast cancer.Methods: We enrolled in a retrospective study involving 72 patients with breast cancer between February 2020 and January 2022. All patients had clinical features of axillary lymph node metastasis and received neoadjuvant therapy. PNI and SII were detected by hematology before and after treatment. Chi-square test was used to compare the clinicopathological and experimental parameters among all groups. Logistic regression analysis was used to evaluate the prognostic value of each factor.Results: The prognosis was evaluated and 18 patients (25%) achieved pathological complete response (pCR) after neoadjuvant therapy. The pCR rate of breast cancer patients was significantly correlated with ER, PR, HER-2, molecular subsets, tumor size, vascular invasion, nerve invasion, N stage, clinical stage and chemotherapy regimen. Low ΔPNI, high ΔSII and higher ΔPNI-ΔSII score values had better prediction of therapeutic effect, especially the ΔPNI-ΔSII score.Conclusion: In breast cancer patients receiving neoadjuvant chemotherapy, ΔPNI-ΔSII score is an effective predictor of efficacy, which helps to identify high-risk groups and evaluate efficacy.

2 February 2024 in Asian Journal of Surgery
Verified
Journal Article
Open access
JJJiali Ji
Jiali Ji
XZXunlei Zhang
Xunlei Zhang
SYShushu Yuan
Shushu Yuan
HLHong Liu
Hong Liu
LYLei Yang
Lei Yang
Background: A comprehensive understanding of gastric signet ring cell carcinoma (SRCC) is limited. The aim of our study was to analyze metastatic patterns of gastric SRCC and evaluate impacts of gastrectomy and chemotherapy for metastatic gastric SRCC. Methods: We obtained data of gastric cancer patients between 2010 and 2017 in the Surveillance, Epidemiology, and End Results database. Chi-square tests were used to compare data significance. Kaplan -Meier, Cox proportional hazards regression and Fine-Gray competing risk analysis were used to analyze the difference in the overall survival (OS) and cancer-specific survival (CSS). Propensity-score matching was used to adjust numerical difference. Results: Among 36,459 eligible gastric cancer patients, 6264 (17.2 %) were SRCC patients. Bone metastasis was more common in SRCC patients than in non-SRCC patients. The multivariate analysis showed that chemotherapy (HR = 0.30, 95 %CI = 0.27-0.33, p < 0.01) and gastrectomy (HR = 0.51, 95 %CI = 0.45 -0.59, p < 0.01) were protective prognostic factors in certain stage IV SRCC patients. For the effect of gastrectomy, survival benefits could be found in patients with liver metastasis. The gastrectomy was not associated with improved OS in patients with lung or multiple metastases. In subgroup analysis, SRCC patients with metastasis who received gastrectomy and chemotherapy (HR = 0.17, p < 0.01; HR = 0.03, p < 0.01) had a better OS and CSS than those who had chemotherapy only (HR = 0.30, p < 0.01; HR = 0.18, p < 0.01). Conclusion: Our study analyzed the unique metastatic patterns of gastric SRCC and recommended chemotherapy as the first choice in metastatic SRCC. For patients with liver metastasis, gastrectomy plus chemotherapy can be considered. (c) 2024 Asian Surgical Association and Taiwan Robotic Surgery Association. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).

1 January 2023 in Cancer Control
Verified
Journal Article
Open access
XZXunlei Zhang
Xunlei Zhang
XQXinyue Qiu
Xinyue Qiu
WZWenjing Zhao
Wenjing Zhao
LSLi Song
Li Song
XZXingsong Zhang
Xingsong Zhang
MTMin Tao
Min Tao
Background: ARID3B (AT-rich interaction domain 3B) has been demonstrated to be associated with the progression and patient prognosis of several human tumors. We conducted the present study to investigate the biological behavior and clinical relevance of ARID3B in gastric cancer (GC). Methods: Detection of the expression level in GC tissues and cell lines were performed by Western blot and immunohistochemistry. We also retrospectively analyzed the correlation of ARID3B with clinicopathological characteristics and patient prognosis in gastric cancer. The biological functions of ARID3B in GC cells were further explored by transwell migration assays, wound healing assays and cell proliferation assay. Results: The present study suggested that the expression of ARID3B was significantly lower in GC tissues than in adjacent normal tissues. IHC staining in tissues of 406 GC patients from training and validation sets verified that ARID3B over-expression correlated with clinicopathological features, such as degree of differentiation and clinical stage. Meanwhile, ARID3B was proved to be an independent prognostic factor for GC prognosis. Furthermore, over-expression of ARID3B suppressed proliferation in GC cells according CCK8 assay. We found that over-expression of ARID3B inhibited GC cell migration by transwell assay and wound healing assay. Furthermore, EMT markers were detected in ARID3B over-expression GC cells, which showed that ARID3B may inhibit metastasis of GC cells. Conclusion: Our results firstly revealed that the expression level of ARID3B was closely correlated with clinicopathological features and may serve as an independent prognostic factor for GC patients. More importantly, ARID3B could suppress GC progression, including cell proliferation, migration and metastasis.

30 September 2019 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
XZXunlei Zhang
Xunlei Zhang
XZXingsong Zhang
Xingsong Zhang
LSLili Shen
Lili Shen
LSLi Song
Li Song
JWJindong Wu
Jindong Wu
BZBin Zhu
Bin Zhu
Colorectal cancer (CRC) is the third most common type of cancer worldwide. Recent studies had revealed the important roles of long non-coding RNAs (lncRNAs) in a variety of human cancers, including CRC. However, the molecular mechanisms associated with CRC remain largely undetermined. In the current study, the GSE21510 dataset was analyzed to identify differentially expressed mRNAs and lncRNAs in CRC samples. The Database for Annotation, Visualization and Integrated Discovery was used to perform Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway bioinformatics analysis. Furthermore, protein-protein interaction networks were constructed to reveal interactions among differentially expressed proteins. Kaplan-Meier analysis was subsequently performed to determine the association between key lncRNA expression and the overall survival of patients with CRC. A total of 107 upregulated lncRNAs and 43 downregulated lncRNAs were identified in CRC. A lncRNA mediated co-expression network was also constructed in CRC. Bioinformatics analysis indicated that lncRNAs were associated with a series of biological processes, including 'xenobiotic glucuronidation', 'rRNA processing', 'sister chromatid cohesion', 'cell proliferation', 'mitotic nuclear division' and 'cell cycle regulation'. Furthermore, a higher expression of small nucleolar RNA host gene 17, tetratricopeptide repeat domain 2B-antisense RNA (AS) 1, erythrocyte membrane protein band 4.1 like 4A-AS2, deleted in lymphocytic leukemia 2, and a lower expression of muscle blind like splicing regulator 1-AS1 and LOC389332 were associated with shorter overall survival time in CRC samples. The present study provides useful information that can be used in the identification of novel biomarkers for CRC.

27 June 2022 in Research Square
Verified
Preprint
Open access
PDF file
JNJingyi Ni
Jingyi Ni
CJConghui Jin
Conghui Jin
XQXue Qi
Xue Qi
WXWeiwei Xu
Weiwei Xu
XLXinghui Li
Xinghui Li
XZXunlei Zhang
Xunlei Zhang
Objective: The objective of this study is to evaluate the efficacy prediction values of systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) in breast cancer patients who received neoadjuvant chemotherapy.Methods: We registered a retrospective study include 72 breast cancer patients between February 2020 and January 2022. All patients had axillary lymph node metastasis receiving neoadjuvant therapy. Calculating PNI, SII before and after therapy were examined through blood routine. Chi-square test was used to compare the clinicopathological and laboratory parameters between groups. Using the logistic regression analysis to evaluate the prognosis values of the factors.Results: 18 patients (25%) achieved pathologic complete response (pCR) after neoadjuvant therapy. The pCR rate of breast patients had significant relationship with ER, PR, HER-2, molecular subgroup, tumor size, vascular invasion, nerve invasion, N stage, clinical stage and chemotherapy regimen. Low ΔPNI, high ΔSII and higher ΔPNI-ΔSII score values had better prediction of therapeutic effect, especially the ΔPNI-ΔSII score.Conclusion: The ΔPNI-ΔSII score may be an effective efficacy prediction index in breast cancer patients receiving neoadjuvant chemotherapy, which can help to identify high-risk groups and efficacy evaluation.